WuXi Biologics (Cayman) Inc. (SEHK:2269) agreed into an Asset Purchase Agreement to acquire Drug Substance Facility in Wuppertal from Bayer Aktiengesellschaft (XTRA:BAYN) for €110 million on December 21, 2020. WuXi Biologics will, on the Completion Date, enter into the Sublease Agreement and the Transitional Service Agreement with Bayer. The aggregate value of the Transaction amounts to approximately €150 million. The consideration to be paid by WuXi Biologics Germany will be funded by the Group's internal financial resources. The transaction is subject to regulatory approval and completion is subject to fulfillment of there being no other foreign trade restriction or prohibition imposed by the relevant governmental authorities on the Acquisition under the applicable laws and either the relevant governmental authorities having given the pre-merger clearance or no such pre-merger filing being necessary under the applicable laws. Completion shall take place on the first business day following the month in which the conditions precedent are fulfilled or waived, provided that it will be no later than September 30, 2021. It is expected that Completion will take place in the first half of 2021. Ulrich Braun, Dirk Siewert, Dominik Schneider, Salvatore Rapisarda, Martin Rock, Christoph Scheiner, Lionel Buddensieg, Tim Mollenhauer, Johannes Hüttner, Markus Dierksmeier, Bartholomäus Aengenvoort, Alexander Leidig, and Matthias Flotmann of Commerzbank acted as financial advisors for Bayer. A team led by Dirk W. Kolvenbach and Michael Pauli, including Mathis Dick, Michael Below, Bodo Dehne, Wolfram Meven, Rainer Velte, Fabian Gerstner and Tobias Plath of Heuking Kühn Lüer Wojtek acted as legal advisor to WuXi Biologics (Cayman) Inc. in the transaction.

WuXi Biologics (Cayman) Inc. (SEHK:2269) completed the acquisition of Drug Substance Facility in Wuppertal from Bayer Aktiengesellschaft (XTRA:BAYN) on May 7, 2021.